(Q47719291)

5 February 2018

title

Prophylactic HPV vaccines: reducing the burden of HPV-related diseases (English)

1 reference

5 February 2018

1 reference

Luisa Lina Villa

1

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 March 2006

1 reference

5 February 2018

published in

Vaccine

1 reference

5 February 2018

volume

24 Suppl 1

1 reference

5 February 2018

page(s)

S23-8

1 reference

5 February 2018

Epidemiology of Genital Human Papillomavirus Infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Determinants of genital human papillomavirus infection in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Counseling and educational interventions for women with genital human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Human papillomavirus vaccines and prevention of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Chapter 16: Prophylactic human papillomavirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Acceptability of human papillomavirus immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.09.001

1 reference

5 February 2018

1 reference

5 February 2018